Key takeaways
Incruse Ellipta (umeclidinium) and Tudorza Pressair (aclidinium) are both long-acting muscarinic antagonists (LAMAs) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Incruse Ellipta is taken once daily, while Tudorza Pressair is taken twice daily. Both medications are available only as brand name medications. Additionally, both medications can cause common cold symptoms and cough, but Tudorza Pressair may also cause headaches and sinus inflammation. Incruse Ellipta has a dose counter that shows 30 doses, while Tudorza Pressair’s inhaler changes color to indicate correct usage. Both medications should not be used for sudden breathing problems and contain milk proteins, which can cause severe allergies in some people.
